Completed PHASE1 INTERVENTIONAL 2-arm NCT00924053

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes

Sponsor: Theracos

Conditions Diabetes Mellitus Type 2

Interventions EGT0001474 Placebo

Updated 9 times since 2017 Last updated: Jun 4, 2019 Started: Jun 30, 2009 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00924053, this PHASE1 trial focuses on Diabetes Mellitus Type 2 and remains completed. Sponsored by Theracos, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jul 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jul 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theracos

Data source: Theracos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States